期刊文献+

高通量端粒酶抑制剂筛选模型融合表达载体的构建及转化

Construction and transformation of fusion expression protein used in high throughput screening model for telomerase inhibitors
下载PDF
导出
摘要 目的构建含不同结构域的人端粒酶逆转录酶(hTERT)酵母三杂交系统融合蛋白表达载体并转化酵母。方法采用PCR法从pCLXSN-hTERT质粒中提取不同的hTERTcDNA片段,纯化分离定向克隆到pYESTrp3质粒,构建包含不同hTERT蛋白结构域的编码序列的重组质粒,转化大肠杆菌,经PCR、酶切、测序鉴定,将阳性重组质粒转化酵母菌,进行毒性和自激活检验。结果经过测序验证,重组融合蛋白表达载体pYESTrp3-hTERT构建成功,转化酵母无毒性和自激活性。结论成功构建能用于酵母三杂交系统的融合蛋白表达载体,可于酵母三杂交系统筛选端粒酶抑制剂及hTERT和hTR间的相互作用。 [Objective] To construct different fusion protein expression vectors to yeast three-hybrid system which contain human telomerase catalytic subunit. [Methods] Different fragments of hTERT eDNA were amplified from pCLXSN-hTERT plasmid and cloned into pYESTrp3 prey plasmids respectively. The recombined prey plasmids were transformed into competent cells of Ecoli, Positive ones were identified by specific PCR, enzyme digestion and DNA sequencing analysis. Finally, the successfully recombined plasmids were transfected into yeast L40ura3 and which was tested for toxicity and serf-activation. [Results] Compared with hTERT gene in GenBank, the homology of the recombined expression vector pYESTrp3-hTERT was 99% in nucleotide acid sequence, no toxicity and self-activation were observed. [Conclusions] Fusion protein expression vectors of hTERT were constructed successfully, which might provide the foundation for research on human telomerase reverse transcriptase in the field of anticancer drug screening and the interaction between hTR and hTERT.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2009年第13期1930-1933,共4页 China Journal of Modern Medicine
基金 国家自然科技基金项目(No:306724487)
关键词 HTERT 酵母三杂交 端粒酶抑制剂 hTERT yeast three-hybrid systems telomerase inhibitor
  • 相关文献

参考文献2

二级参考文献19

  • 1Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancers [J]. Science, 1994, 266:2011 - 2015. 被引量:1
  • 2Doyle LA, Highsmith WE. Telomerase as a diagnostic and therapeutic target for cancer [J]. Expert Rev Anticancer Ther,2002, 2:217 - 225. 被引量:1
  • 3Komata T, Kanzawa T, Kondo Y. et al.Telomerase as a therapeutic target for malignant gliomas [J]. Oncogene, 2002,21 : 656 - 663. 被引量:1
  • 4Vonderheide RH, Hahn WC, Schuhze JL,et al. The telomerase catalytic subunit is widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes [J]. Immunity, 1999, 10:673 - 679. 被引量:1
  • 5Vonderheide RH. Telomerase as a universal tumor-associated antigen for cancer immunotherapy [J] . Oncogene,2002, 21:674 - 679. 被引量:1
  • 6Ducrest AL, Szutorisz H, Lingner J, et al.Regulation of the human telomerase reverse transcriptase gene [J ]. Oncogene,2002, 21:541 -552. 被引量:1
  • 7Harley CB. Telomerase is not an oncogene [J]. Oncogene, 2002, 21:494 - 502. 被引量:1
  • 8Arai J, Yasukawa M, Ohminami H, et al.Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-24-restricted antileukemia cytotoxic T lymphocytes [J]. Blood, 2001, 97:2903 - 2907. 被引量:1
  • 9Scardino A, Gross DA, Alves P, et al.HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immmnotherapy [J]. J Immunol, 2002,168:5900 - 5906. 被引量:1
  • 10Vonderheide RH, Anderson KS, Hahn WC, et al. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase [J]. Clin Cancer Res,2001, 7:3343 - 3348. 被引量:1

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部